Registration Questions

Call: 202-684-2034
Email: eventregistration@bisnow.com

Request Speaker Information

Speaker Topics

Tell us a Little More

Speakers and Panels

Beyond the Building: Creating Campuses Where Life Sciences Companies Choose to Stay

Robert Evans
1.6m sq ft expansion underway at Hinxton

Robert Evans

Chief Executive Officer

Wellcome Genome Campus

Keith Purdie
Home to 130+ companies & counting

Keith Purdie

Senior Director of Development and Operations

Cambridge Science Park

Sarah Cary
£200m White City Innovation Centre JV

Sarah Cary

Chief Development Officer

Imperial College London

Ruth Pardoe
Acquiring & Developing Key UK Assets

Ruth Pardoe

Senior Asset Manager

Royal London Asset Management

Keith Purdie

Home to 130+ companies & counting

Cambridge Science Park

Keith Purdie is Senior Director of Development & Operations at Cambridge Science Park, where he leads key aspects of the Park’s operational strategy and supports delivery of its long-term masterplan.

Cambridge Science Park is the UK’s longest-established science park and home to more than 130 organisations spanning life sciences, technology, and related sectors. Keith’s role brings together estate operations, occupier experience, infrastructure, sustainability, and stakeholder engagement, with a particular focus on creating the conditions in which innovative businesses can establish themselves, grow and remain within the Park.

Before joining Cambridge Science Park, Keith was Site Director at Colworth Science Park, where he worked closely with occupiers, operators, and regional partners to develop the campus ecosystem and support businesses across the food, biotechnology, and life sciences sectors. His wider experience includes economic development, skills, and employer engagement, and he is a Fellow of the Royal Society of Arts.

Sarah Cary

£200m White City Innovation Centre JV

Imperial College London

Sarah is responsible for Imperial’s capital development programme as well as the management of Imperial’s non-academic innovation and residential properties. This includes leading plans for a new mixed-use 22-acre campus in White City which blends academic, commercial, and residential activity around a new community park. Sarah has a PhD in town planning and was previously Executive Director Place at Enfield Council after holding various roles in British Land.

Wet Lab, Dry Lab, Wrong Lab?: Are We Overbuilding, Underbuilding, or Just Building the Wrong Thing?

Barry Jessup
London Cancer Hub; £1bn planning consent

Barry Jessup

Managing Director

Socius

Mark Swetman
Canary Wharf 200,000 sq ft lab retrofit

Mark Swetman

CEO

LS Estates

Simon Francis
New Knowledge Quarter HQ

Simon Francis

Director of Estates & Facilities

LifeArc

Priya Shah
15+ years GMP pharma & lab delivery

Priya Shah

Director Life Sciences & Laboratories, UK

Merrick

Manisha Kulkarni
Lab fit-out and design specialists

Manisha Kulkarni

Director of Science & Technology

Bulb

Tim Fry
Moderator

Tim Fry

Business Leader | Science UKIMEA

ARUP UK

Barry Jessup

London Cancer Hub; £1bn planning consent

Socius

Barry brings over 25 years of expertise in complex urban development, having contributed to prominent projects throughout London and the South of the UK.

His real estate journey began at Lendlease, where he worked on significant developments like Bluewater, Chapelfield, and Greenwich Peninsula. Barry subsequently played a foundational role at First Base, elevating it to a top-tier mixed-use developer and ascending to CEO in 2020.  First Base was involved in some of the highest profile and most innovative developments in London including Adelaide Wharf, the setting for a BBC film, KX Nido an early Kings Cross project, and East Village the transformation of the Athlete’s Village at the Olympic Park.

In 2021, Barry founded Socius, an urban development company dedicated to genuinely impactful mixed-use regeneration. Established as an early ‘B Corp’, Socius has since built up a £2.5bn pipeline of projects in growth cities across the South including Botanic Place and Mill Yard in Cambridge, the London Cancer Hub in Sutton and Edward Street Quarter in Brighton.

Barry's commitment to creating great places and experiences ramped up further in 2023 when he founded Populate, a dedicated place management operating company. Populate is now adding people to places and creating new and better user experiences, ranging from street markets in Brighton to research ecosystems in Sutton.

His strategic vision and leadership have not only set new standards in the industry but have also demonstrated that it is possible to create meaningful social and environmental impact whilst also delivering strong investor returns, which means that the approach and model is replicable.

Mark Swetman

Canary Wharf 200,000 sq ft lab retrofit

LS Estates

Mark Swetman is the Chief Executive Office at LS Estates, a developer focused on retrofit and sustainable redevelopment for offices and life sciences in Central London. Established in 2014, Mark saw an opportunity to establish a boutique central London operator to work with both local and international capital sources. He has over 25 years of direct real estate experience, the majority of which acting as a principal with significant new business and development roles at Hammerson plc and at Hines both in central London and in Paris. Mark has a degree in Real Estate from Oxford Brookes University and a Masters in Finance from City University and is a member of the RICS.

Priya Shah

15+ years GMP pharma & lab delivery

Merrick

Priya is a Chartered Chemical Engineer, who has over 15 years’ experience working on high profile projects within a number of highly regulated sectors including pharmaceutical, industrial gases and nuclear. Over the last 9 years, she has managed large-scale projects within the life sciences sector for a number of pharmaceutical clients, and over this time has amassed extensive knowledge and expertise in the successful delivery of complex pharmaceutical manufacturing and life sciences real estate projects. In her current role at Merrick, Priya is leading growth in the UK and European life sciences, pharmaceutical and laboratory markets by increasing local presence and capability while also ensuring clients are receiving the highest quality of architecture and engineering design services and technical quality and operational performance consulting services.

Manisha Kulkarni

Lab fit-out and design specialists

Bulb

Manisha Kulkarni is Director of Science & Technology at Bulb, with over 25 years of experience in scientific research and laboratory design across the pharmaceutical, chemical, and construction sectors. She holds a PhD in Organic Chemistry and brings deep expertise in translating complex scientific requirements into high-performing, future-ready laboratory environments. At Bulb, she advises on lab design, workflow optimisation, and regulatory frameworks, helping bridge the gap between science and the built environment.

Tim Fry

Moderator

ARUP UK

Tim leads the science business area, across the UKIMEA region for Arup. He leads on strategy and

business development, maintains relationships with clients and manages a portfolio of projects.

Tim is a chartered engineer and experienced team leader, having led multi-discipline teams in

delivering engineering solutions on complex highly serviced buildings from concept design phases

through to fully coordinated detail design and construction.

He has been involved in science buildings from his first project over 28 years ago, working on the

design and construction of a facility to produce injectable vaccines. As well as other manufacturing

projects experience, Tim has been involved in the design of many research and development

laboratories for a range of science users and scales of project. These have been for private clients,

government institutes and higher education establishments.

Tim thrives in solving client’s challenges bringing a wealth of experience to provide robust, energy

efficient and sustainable design solutions, applying his knowledge of construction, commissioning

and maintenance.

Three Tenants: Leasing for Pharma, Bioprocessing and the AI Cohort

Amy Hockley
Acquired Life Sciences REIT, 694,300 sq ft

Amy Hockley

Head of Innovation Leasing

British Land

Carl Williams
1m sq ft Class A lab pipeline, Cambridge

Carl Williams

Director, UK Asset & Property Management

BioMed Realty

Henry Shearer
King's Cross; home to Francis Crick Institute

Henry Shearer

Head of Office and Investment, King’s Cross

King's Cross Group

Amy Hockley

Acquired Life Sciences REIT, 694,300 sq ft

British Land

Amy Hockley is a Head of Innovation Leasing at British Land with responsibility for workspace leasing across our 7.5m Central London portfolio; including the 53 acre Canada Water masterplan and more recently Innovation Campuses.

Amy has been in this role since 2016, having previously worked as a Director in the Tenant Advisory Team at CBRE, advising occupiers on leasing strategies and transaction in Central London. The experience gained in working with occupiers has motivated Amy to focus on a collaborative approach between occupier and landlord; delivering building design with the end user at the core of decisions and flexible solutions to real estate needs that respond to business drivers. Amy has a strong interest in workplace design and customer experience.

Henry Shearer

King's Cross; home to Francis Crick Institute

King's Cross Group

Under Henry’s leadership, King’s Cross is bringing forward a range of office spaces to lease. These include space at Western Transit Shed, Two Pancras Square and The Jellicoe, where the neighbourhood is delivering new purpose-built flexible workspace in partnership with Fora (formerly The Office Group) as it continues to evolve its product offer to office occupiers.

Henry brings almost two decades of experience and leadership across commercial real estate investment, development, leasing and asset management, including roles as Head of UK and Vice President for Offices, Retail and Life Sciences at Oxford Properties Group. During his almost 10-year tenure, he played a pivotal role in growing the company’s office and retail platform in the UK.

Where Is the Next UK Lab Coming From and Who’s Investing?

Artem Korolev
1m sq ft Cherry Hinton Science District

Artem Korolev

Founder and CEO

Mission Street

Pete Wilder
JV with Pioneer Group and Crown Estate

Pete Wilder

Head of Property & Operations

Oxford Science Enterprises

Harry Pickering
4m sq ft, 12 campuses

Harry Pickering

Head of UK Investment

Pioneer Group

Matthew Weiner
£1.5bn investment commitment

Matthew Weiner

Strategic Investment Adviser

The Crown Estate

Candice Blackwood
Moderator

Candice Blackwood

Partner,Head of Healthcare & Life Science Real Estate

CMS

Artem Korolev

1m sq ft Cherry Hinton Science District

Mission Street

Artem founded Mission Street in 2017. Building on extensive track record across investment, development and finance, he has overall strategic responsibility for the growth of the company, project delivery and management.

Prior to Mission Street, Artem was Head of UK Acquisitions and a member of the founding team of GreenOak Real Estate (now BGO), a major international real estate investment and asset management firm (at the time c. £10 Bn under management). He also previously worked for Morgan Stanley in their UK Real Estate team.

Artem’s track record spans development, asset management, real estate private equity and finance. This has included property acquisitions and corporate M&A, leading end-to-end delivery of complex development and asset management projects across the UK, and structuring debt and equity financing (both as the operating partner and capital partner).

Artem graduated with an MA (First Class Honours) in Land Economy at the University of Cambridge and sits on the Investment and Development Committee for the Institute of Cancer Research.

Candice Blackwood

Moderator

CMS

Candice leads our Healthcare and Life Science Real Estate team advising on Hospitals (NHS and Private), Care Homes, GP polyclinics, and lab facilities throughout the UK. She specialises in large scale investment and development transactions acting for the private and public sectors. She has acted regularly on repeat investment from US REITS, international Private Equity investors and UK pension funds, on complex UK cross border real estate acquisitions, disposals, joint ventures, institutional investments, and urban regeneration mixed use developments.

Beyond the Golden Triangle: The Regional Manufacturing Bet

Brad Topps
Greenheys, BHIC and White City all delivered 2025/26

Brad Topps

Project Director, Sister Manchester & Chief Commercial Officer

Bruntwood Scitech

Kerry Walker
£100m Phase 3; 285,000 sq ft now operational

Kerry Walker

Managing Director

NETPark: North East Technology Park

Seb Loyn
Brabazon: Mixed-use Science & Tech Hub

Seb Loyn

Director of Planning & Development

YTL Developments

Lisa Hannon
Leading Edinburgh BioQuarter

Lisa Hannon

Team Leader, Property

Scottish Enterprise

Brad Topps

Greenheys, BHIC and White City all delivered 2025/26

Bruntwood Scitech

Brad is the Project Director for Sister, Manchester’s ambitious new £1.7bn innovation district, where he leads the delivery team across innovation, property development, and commercial strategy.

In his role as Chief Commercial Officer at Bruntwood SciTech - the UK’s leading developer of innovation ecosystems - Brad has spent over a decade championing the growth of the science and technology sector. He’s played a pivotal role in nurturing some of Manchester’s most exciting home-grown businesses, while also attracting major global names to the UK, including Uber, Disney, Octopus Energy, Roku, and Puma.

A passionate advocate for inclusive innovation, Brad is committed to ensuring that the economic growth of the city directly benefits local communities and creates opportunities for all. 

Kerry Walker

£100m Phase 3; 285,000 sq ft now operational

NETPark: North East Technology Park

Kerry Walker is Managing Director of Business Durham, where she leads Durham’s inward investment, business support, economic development and commercial property programmes. With more than two decades of experience delivering economic growth across the North East, she has successfully led major regeneration schemes, investment projects and business growth initiatives that have generated lasting economic impact.

Kerry is responsible for driving Business Durham’s ambitious growth agenda, including the ongoing development of NETPark, the county’s nationally significant science and technology park, and a portfolio of strategic employment sites and commercial property assets. She is passionate about using investment, innovation and placemaking to create the conditions for sustainable growth, helping businesses to thrive while attracting new investment and opportunities to Durham.

Seb Loyn

Brabazon: Mixed-use Science & Tech Hub

YTL Developments

Having trained in both Architecture and Planning, Seb has spent a career at some of the property industry’s most innovative developers, starting out at Urban Splash, Skanska and Studio Hive before joining YTL Developments in 2017. 

He now leads the team responsible for one of the most exciting regeneration projects in the country. He is also a Trustee of Design West, which champions quality design and placemaking across the South West.  

Lisa Hannon

Leading Edinburgh BioQuarter

Scottish Enterprise

Lisa Hannon leads Scottish Enterprise’s work on strategic property and innovation infrastructure projects, supporting the development of Scotland’s next generation of science, technology and innovation districts. Working at the intersection of public policy, investment and real estate, she helps shape projects that create the conditions for private sector investment, company growth and long-term economic impact.

Her portfolio includes major life sciences and innovation assets such as Edinburgh BioQuarter and Dundee Lifesciences Innovation Hub. Lisa works closely with investors, developers, universities, health institutions and government partners to deliver investment-ready sites and infrastructure that support Scotland’s ambitions in life sciences, advanced manufacturing and innovation-led growth.

Presentation by McLaughlin & Harvey: The UK’s most developable life sciences locations – realising opportunities in the Golden Triangle and beyond

Alan Mackenzie

Alan Mackenzie

Life Sciences Bid Director

McLaughlin & Harvey

Jake Nunley

Jake Nunley

Cities Specialist

ING

Alan Mackenzie

Life Sciences Bid Director

McLaughlin & Harvey

Alan is a Bid Director for McLaughlin & Harvey’s preconstruction department and has 40 years’ construction experience spanning commercial, higher education and healthcare sectors.

Drawing on this experience, Alan drives McLaughlin & Harvey’s Life Science presence, working collaboratively with key stakeholders to develop strategic offerings to clients, which blends the company’s historical office and laboratory experience with current specialisms and expertise.

Jake Nunley

Cities Specialist

ING

Jake is a Cities Specialist at strategic communications consultancy ING, where he leads the firm’s flagship Most Talked About Cities research and helps cities and city-shaping organisations deliver thought leadership and implement long-term strategies.

With nine years’ experience supporting local governments, regional investment organisations and infrastructure leaders across 30+ cities internationally, he specialises in market analysis, sector mapping, and stakeholder engagement.

Prior to joining ING, Jake led the research team at bespoke urban consultancy The Business of Cities, where he oversaw and managed the world’s largest database of city performance benchmarks and delivered reports on the geography of innovation for the World Economic Forum, JLL and the Connected Places Catapult. Jake has also delivered guest lectures for UCL’s MPA in Urban Innovation and Policy on how business and business techniques help the built world to succeed.

The UK Life Sciences Sector Is Being Rebuilt From the Ground Up. Literally.

The UK life sciences sector is in the middle of a structural shift that comes along once in a generation. A government committing up to £1 billion in manufacturing and R&D investment. A biotech VC market recovering sharply, with £552 million raised in Q1 2026 alone, up 17% quarter-on-quarter. Clinical trial reform cutting setup times from 250 days to 122. And a wave of international M&A  - from Eli Lilly to Amgen - validating UK-originated science assets at the highest levels.
 

Behind all of it is real estate. 3.7 million square feet of lab and innovation space under construction across London, Oxford and Cambridge. A £1 billion expansion at the London Cancer Hub. A £3 billion land deal at the Cambridge Biomedical Campus. And a pipeline of new clusters, from Whitechapel to White City, from Manchester to the Oxford-Cambridge Arc, transforming where UK science happens and who profits from it.
 

For CRE professionals, this is the moment. The deals are moving. The capital is flowing. The occupiers — biotechs, pharma, academia, NHS — are actively looking for space. The question is not whether this sector will grow. The question is who will be in the room when it does.

Five Questions This Summit Will Answer

- Where are the real investment opportunities in UK life sciences real estate — and which markets are already overheated?
- How is the government's £1 billion life sciences investment programme reshaping development economics — and how can developers and investors access it?
- What do life sciences occupiers actually need from their real estate in 2026 — and are developers building the right product?
- As M&A activity accelerates and UK biotech assets attract global acquirers, how does that reshape the occupier base — and what does it mean for lease risk?
- How are the UK's emerging clusters — Manchester, Birmingham, the Oxford-Cambridge Arc — closing the gap on London, and what does a winning regional life sciences strategy actually look like?

How You'll Do More Business

The UK life sciences real estate market is not a niche. It is the fastest-growing, most policy-backed, most internationally validated commercial real estate opportunity in Britain right now — and the window to establish position is compressing fast. The developers, investors, and advisors who build relationships in this sector today will be the ones executing the deals of the next decade. This summit exists to accelerate that process.

 Featured Article:


Questions about your ticket purchase or interested in sponsoring? Reach out to customerservice@bisnow.com for customer support.

For questions, recommendations, comments, or press inquiries please email our VP of Production, Elizabeth Baker, at liz.baker@bisnow.com

To request disability-related accommodations, please contact lucrezia.manzo@bisnow.com no later than seven business days before the event.

Agenda

Time Activity
8:00 AM
8:55 AM
Registration, Networking, and Breakfast
8:55 AM
9:00 AM
Welcome from Bisnow!
9:00 AM
9:40 AM
Where Is the Next UK Lab Coming From and Who’s Investing?

UK life sciences entered 2026 with returning venture capital, billion-dollar pharma acquisitions and half a billion pounds in government manufacturing grants. This panel asks where the next wave of lab demand actually comes from, what a market driven by acquisitions rather than IPOs means for the leases institutional investors are being asked to underwrite, and whether the assets being built today are the ones investors and occupiers are interested in.

9:40 AM
9:50 AM
Presentation by McLaughlin & Harvey: The UK’s most developable life sciences locations – realising opportunities in the Golden Triangle and beyond
9:50 AM
10:30 AM
Three Tenants: Leasing for Pharma, Bioprocessing and the AI Cohort

AI companies are competing for the same buildings life sciences companies want. With BioMed Realty, British Land and King's Cross Central in the room, this panel asks who is actually signing leases right now and what it means when an AI firm outbids a biotech for a lab-spec floor.

10:30 AM
10:50 AM
Networking Break!
10:50 AM
11:30 AM
Beyond the Golden Triangle: The Regional Manufacturing Bet

The big science and tech money is no longer just going to London, Oxford and Cambridge. This panel looks at why cities like Manchester, Bristol, and Sedgefield, as well as cities in Scotland, are attracting serious investment, and what it actually takes to build facilities for vaccines, tech innovation, defence spaces, research labs and more. Where will the next major facility land?

11:30 AM
12:10 PM
Wet Lab, Dry Lab, Wrong Lab?: Are We Overbuilding, Underbuilding, or Just Building the Wrong Thing?

Wet labs cost up to five times more to fit out than dry labs, and AI computers are pushing power demands toward data centre territory. This panel asks whether developers can still build one building that works for all three tenant types, or whether the era of the flexible, all-purpose science and tech buildings are the future.

12:12 PM
1:30 PM
Lunch and Networking Break!
1:30 PM
2:10 PM
Beyond the Building: Creating Campuses Where Life Sciences Companies Choose to Stay

The best life sciences campuses are communities, not just buildings. With the Wellcome Genome Campus, Cambridge Science Park, Imperial College London and Royal London Asset Management in the room, this panel asks what separates the campuses occupiers fight to get into from the ones they treat as a stepping stone.

2:10 PM
3:30 PM
Closing Networking and Drinks!

Venue

Park Plaza London Westminster Bridge
200 Westminster Bridge Rd
London SE1 7UT

Function Room: Westminster Ballroom

Floor: - 1

Get Directions

Tickets

General Admission

£299.00 /ticket

Act now, there are still some tickets available.

Gold Sponsors